u/DM-McMike · 321d agono track record yet
INTS - Strong Buy 🚀
INTS published peer-reviewed clinical data showing their tumor-injected therapeutic extended median survival from 3 to 18 months in heavily pretreated advanced cancer patients with 83% disease control rate. The company has achieved a major breakthrough after 13 years of R&D, positioning it for acquisition by major pharma.
At post $33.00Now $3.81-88.5% since postedas of Sep 16, 4:30 PM ET